Acute Rise of Pancreatic Polypeptide after Electroconvulsive Therapy

1982 ◽  
Vol 141 (1) ◽  
pp. 24-26 ◽  
Author(s):  
J. M. Allen ◽  
T. E. Adrian ◽  
P. A. Cramer ◽  
J. Steinert ◽  
S. R. Bloom
Keyword(s):  
Electroconvulsive Therapy ◽  
Pancreatic Polypeptide ◽  
Vagal Stimulation ◽  
Cholinergic Tone ◽  
Dramatic Rise

SummaryPlasma pancreatic polypeptide concentrations rise by 320±81 per cent following administration of electroconvulsive therapy. This rise is observed in the first ten minutes despite premedication of patients with 0.6 mg atropine. Pancreatic polypeptide release is dependent on cholinergic tone and is very sensitive to atropine. The dramatic rise in pancreative polypeptide observed following electroconvulsive therapy probably results from vagal stimulation and reflects insufficient atropine premedication.

Central cholinergic regulation of pancreatic polypeptide secretion in conscious dogs

1997 ◽  
Vol 154 (2) ◽  
pp. 311-317 ◽  
Author(s):  
M Okita ◽  
A Inui ◽  
S Baba ◽  
M Kasuga
Keyword(s):  
Food Intake ◽  
Pancreatic Polypeptide ◽  
Atropine Sulfate ◽  
Basal Secretion ◽  
Cholinergic Mechanisms ◽  
Glucose Levels ◽  
Plasma Pretreatment ◽  
Cephalic Phase ◽  
Cholinergic Tone ◽  
Blood Glucose Concentrations

Abstract The secretion of pancreatic polypeptide (PP) is regulated by fluctuations in blood glucose concentrations and food intake, in which vagal-cholinergic mechanisms play an important role, especially for the cephalic phase of PP secretion. In this study, we examined whether central cholinergic mechanisms are also important for PP secretion by relaying information in the brain to the vagus nerve and the muscarinic cholinergic receptors in the pancreas. Atropine sulfate (20–200 μg) was administered into the lateral cerebral ventricle and its effects on the basal secretion of PP as well as the secretions stimulated by insulin-induced hypoglycemia (Actrapid MC, 0·25 U/kg) and a mixed meal (243 kcal) were studied in seven dogs. Intralateral cerebroventricular (ILV) atropine (100 and 200 μg) abolished the fluctuations in basal PP secretion without appearing in the plasma. Pretreatment with 20, 100, and 200 μg ILV atropine significantly decreased the PP response to insulin-induced hypoglycemia, with the integrated PP response to 58, 32, and 26% of that of controls respectively. Atropine (100 μg ILV) significantly reduced the postprandial PP secretion in both the cephalic and the gastrointestinal phases, whereas increased insulin and glucose levels were unaffected. Centrally administered atropine was able to suppress the basal secretion of PP as well as the secretions stimulated by hypoglycemia and food intake. These findings suggest that (1) the spontaneous release of PP is governed by an oscillating, central cholinergic tone, and (2) the stimulating PP secretion is, at least in part, regulated by the central cholinergic system. Journal of Endocrinology (1997) 154, 311–317

The importance of cholinergic tone in the release of pancreatic polypeptide by gut hormones in man

Life Sciences ◽  
1979 ◽  
Vol 24 (21) ◽  
pp. 1989-1993 ◽  
Author(s):  
T.E. Adrian ◽  
H.S. Besterman ◽  
S.R. Bloom
Keyword(s):  
Pancreatic Polypeptide ◽  
Gut Hormones ◽  
Cholinergic Tone

Effect of Acute Hyperglycaemia on Basal and Fat-Induced Exocrine Pancreatic Secretion in Humans

1997 ◽  
Vol 93 (6) ◽  
pp. 573-580 ◽  
Author(s):  
W. F. Lam ◽  
E. S. M. Muller ◽  
J. H. M. Souverijn ◽  
C. B. H. W. Lamers ◽  
A. A. M. Masclee
Keyword(s):  
Pancreatic Polypeptide ◽  
Healthy Subjects ◽  
Biliary Secretion ◽  
Exocrine Pancreatic Secretion ◽  
Indirect Measure ◽  
Acute Hyperglycaemia ◽  
Basal Period ◽  
Cholinergic Tone ◽  
Plasma Cholecystokinin ◽  
Hormonal Stimulus

1. We have investigated the effect of acute hyperglycaemia on pancreatico-biliary secretion in healthy subjects. Duodenal outputs of trypsin, lipase, amylase, bicarbonate and bilirubin were measured for 90 min under basal conditions and for 90 min in response to intrajejunal fat administration (1 g/h) on 2 separate days: during normoglycaemia (blood glucose 5 mmol/l) and during acute hyperglycaemia aimed at 15 mmol/l. Plasma cholecystokinin levels, as the major hormonal stimulus of pancreatic and biliary secretion, and plasma pancreatic polypeptide levels, as an indirect measure of vagal-cholinergic tone, were determined at regular intervals. 2. In the basal period pancreatico-biliary secretion was significantly (P < 0.05) reduced during hyperglycaemia compared with normoglycaemia. During normoglycaemia and hyperglycaemia intrajejunal fat significantly (P < 0.05) stimulated pancreaticobiliary secretion. However, during hyperglycaemia, fat-stimulated 90 min pancreatico-biliary secretion was significantly (P < 0.05) reduced compared with normoglycaemia: trypsin (23 ± 7 units versus 66 ± 20 units), lipase (36 ± 8 k-units versus 74 ± 18 k-units), amylase (8 ± 2 k-units versus 18 ± 5 k-units) and bilirubin (32 ± 8 μmol versus 71 ± 14 μmol). Plasma cholecystokinin levels increased significantly (P < 0.05) during fat administration and were not different between the two experiments. Plasma pancreatic polypeptide levels were significantly (P < 0.05) reduced during hyperglycaemia both in the basal period and during intrajejunal fat administration. 3. It is concluded that basal and fat-stimulated pancreatico-biliary secretion are significantly reduced during acute hyperglycaemia. Acute hyperglycaemia does not affect intrajejunal fat-stimulated cholecystokinin secretion. Acute hyperglycaemia inhibits basal and stimulated pancreatic polypeptide secretion suggesting vagal-cholinergic inhibition of pancreatico-biliary secretion during hyperglycaemia.

Circadian coupling between pancreatic secretion and intestinal motility in humans

2001 ◽  
Vol 280 (2) ◽  
pp. G273-G278 ◽  
Author(s):  
Jutta Keller ◽  
Gabriele Gröger ◽  
Leelamma Cherian ◽  
Britt Günther ◽  
Peter Layer
Keyword(s):  
Pancreatic Polypeptide ◽  
Pancreatic Secretion ◽  
Intestinal Motility ◽  
Plasma Concentrations ◽  
Pancreatic Enzyme ◽  
Secretory Activity ◽  
Exocrine Secretion ◽  
Motility Index ◽  
Cholinergic Tone ◽  
Pancreatic Exocrine

Human interdigestive intestinal motility follows a circadian rhythm with reduced nocturnal activity, but circadian pancreatic exocrine secretion is unknown. To determine whether circadian changes in interdigestive pancreatic secretion occur and are associated with motor events, pancreatic enzyme outputs, proximal jejunal motility, and plasma pancreatic polypeptide concentrations were measured during consecutive daytime and nighttime periods (12 h each) in seven healthy volunteers using orojejunal multilumen intubation. Studies were randomly started in the morning or evening. Nocturnally, motility decreased (motor quiescence: 67 ± 22 vs. 146 ± 37 min; motility index: 3.59 ± 0.33 vs. 2.78 ± 0.40 mmHg/min; both P < 0.05) but amylase output increased (273 ± 78 vs. 384 ± 100 U/min; P < 0.05) and protease output remained unchanged ( P > 0.05); consequently, enzyme/motility ratio increased. Amylase outputs were always lowest during phase I. Motor but not pancreatic circadian activities were associated with sleep. Pancreatic polypeptide plasma concentrations were unchanged. Consequently, intestinal motor and pancreatic exocrine functions may have different circadian rhythms, i.e., decreased motor and stable secretory activity during the night. However, the association between individual phases of interdigestive motor and secretory activity is preserved. The nocturnal increase in enzyme/motility ratio is probably not caused by increased cholinergic tone.

A Case of Catatonia in a 14-Year-Old Girl with Schizophrenia Treated with Electroconvulsive Therapy

2013 ◽  
Vol 41 (1) ◽  
pp. 69-74 ◽  
Author(s):  
Frank Häßler ◽  
Olaf Reis ◽  
Steffen Weirich ◽  
Jacqueline Höppner ◽  
Birgit Pohl ◽  
...  
Keyword(s):  
Case Report ◽  
Treatment Response ◽  
Electroconvulsive Therapy ◽  
Rating Scale ◽  
Combined Treatment ◽  
Adolescent Patient

This article presents a case of a 14-year-old female twin with schizophrenia who developed severe catatonia following treatment with olanzapine. Under a combined treatment with amantadine, electroconvulsive therapy (ECT), and (currently) ziprasidone alone she improved markedly. Severity and course of catatonia including treatment response were evaluated with the Bush-Francis Catatonia Rating Scale (BFCRS). This case report emphasizes the benefit of ECT in the treatment of catatonic symptoms in an adolescent patient with schizophrenic illness.

Electroconvulsive Therapy: Something for Everyone

1994 ◽  
Vol 39 (1) ◽  
pp. 39-40
Author(s):  
P. V. Nickell
Keyword(s):  
Electroconvulsive Therapy
Sign in / Sign up

Export Citation Format

Share Document